EAH.L
ECO Animal Health Group plc [EAH.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EAH.L Stock Summary
Top 10 Correlated ETFs
EAH.L
Top 10 Correlated Stocks
EAH.L
In the News
EAH.L Financial details
Company Rating
Neutral
Market Cap
64.36M
Income
-845K
Revenue
167.04M
Book val./share
1.2
Cash/share
0.3
Dividend
-
Dividend %
-
Employees
234
Optionable
No
Shortable
Yes
Earnings
08 Jul 2024
P/E
23.77
Forward P/E
-
PEG
10
P/S
0.86
P/B
0.88
P/C
314.13
P/FCF
7.41
Quick Ratio
0.98
Current Ratio
3.36
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-247.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-32.96%
Revenue last 5Y
4.87%
Revenue Q/Q
-24.66%
EPS Q/Q
310.64%
-
-
-
-
SMA20
7.95%
SMA50
-12.04%
SMA100
-13.64%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
4%
ROC
0.05%
Gross Margin
45%
Oper. Margin
6%
Profit Margin
4%
Payout
59%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
82.665-125.0
52W High
-24.61%
52W Low
+14.93%
RSI
55
Rel Volume
0.14
Avg Volume
161.46K
Volume
23.18K
Perf Week
0.79%
Perf Month
1.33%
Perf Quarter
-13.14%
Perf Half Y
-15.48%
-
-
-
-
Beta
0.069
-
-
Volatility
1.92%, 4.32%
Prev Close
1.33%
Price
94.24
Change
-0.8%
EAH.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.01 | 1.07 | 1.56 | 1.21 | 1.26 | |
| Net income per share | 0.11 | 0.06 | 0.11 | -0.01 | 0.01 | |
| Operating cash flow per share | 0.09 | 0.07 | 0.18 | -0.01 | 0.24 | |
| Free cash flow per share | 0.09 | 0.02 | 0.16 | -0.05 | 0.15 | |
| Cash per share | 0.25 | 0.18 | 0.29 | 0.21 | 0.32 | |
| Book value per share | 1.26 | 1.11 | 1.21 | 1.21 | 1.23 | |
| Tangible book value per share | 0.73 | 0.39 | 0.61 | 0.62 | 0.62 | |
| Share holders equity per share | 1.26 | 1.11 | 1.21 | 1.21 | 1.23 | |
| Interest debt per share | 0.03 | 0.06 | 0.03 | 0.03 | 0.08 | |
| Market cap | 293.89M | 148.57M | 217.88M | 109.7M | 65.35M | |
| Enterprise value | 278.8M | 140.49M | 199.88M | 97.3M | 48.17M | |
| P/E ratio | 40.52 | 38.14 | 29.7 | -159.91 | 64.83 | |
| Price to sales ratio | 4.37 | 2.06 | 2.06 | 1.33 | 0.77 | |
| POCF ratio | 46.85 | 32.94 | 17.99 | -306.43 | 4.08 | |
| PFCF ratio | 51.5 | 91.26 | 19.74 | -33.81 | 6.52 | |
| P/B Ratio | 3.48 | 1.99 | 2.66 | 1.34 | 0.78 | |
| PTB ratio | 3.48 | 1.99 | 2.66 | 1.34 | 0.78 | |
| EV to sales | 4.15 | 1.95 | 1.89 | 1.18 | 0.56 | |
| Enterprise value over EBITDA | 22.94 | 17.62 | 10.73 | 14.92 | 6.5 | |
| EV to operating cash flow | 44.44 | 31.15 | 16.51 | -271.78 | 3.01 | |
| EV to free cash flow | 48.85 | 86.29 | 18.11 | -29.98 | 4.8 | |
| Earnings yield | 0.02 | 0.03 | 0.03 | -0.01 | 0.02 | |
| Free cash flow yield | 0.02 | 0.01 | 0.05 | -0.03 | 0.15 | |
| Debt to equity | 0.02 | 0.05 | 0.02 | 0.02 | 0.05 | |
| Debt to assets | 0.02 | 0.04 | 0.01 | 0.02 | 0.04 | |
| Net debt to EBITDA | -1.24 | -1.01 | -0.97 | -1.9 | -2.32 | |
| Current ratio | 4.04 | 3.33 | 3.79 | 4.12 | 3.36 | |
| Interest coverage | 81.19 | 45.81 | 55.96 | 15.94 | 7.71 | |
| Income quality | 0.86 | 1.16 | 1.65 | 0.52 | 15.88 | |
| Dividend Yield | 0.03 | 0.06 | 0 | 0.03 | 0.03 | |
| Payout ratio | 1.07 | 2.16 | 0.08 | -4.21 | 1.8 | |
| Sales general and administrative to revenue | 0.17 | 0.23 | 0.24 | 0.29 | 0.33 | |
| Research and developement to revenue | 0.09 | 0.12 | 0.08 | 0.11 | 0.07 | |
| Intangibles to total assets | 0.39 | 0.54 | 0.46 | 0.46 | 0.44 | |
| Capex to operating cash flow | -0.09 | -0.64 | -0.09 | 8.06 | -0.37 | |
| Capex to revenue | -0.01 | -0.04 | -0.01 | -0.04 | -0.07 | |
| Capex to depreciation | -0.23 | -1.96 | -0.62 | -1.45 | -2.54 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Graham number | 1.76 | 1.2 | 1.72 | 0.53 | 0.64 | |
| ROIC | 0.1 | 0.07 | 0.16 | -0.03 | 0.04 | |
| Return on tangible assets | 0.11 | 0.08 | 0.12 | -0.01 | 0.01 | |
| Graham Net | 0.4 | 0.35 | 0.53 | 0.47 | 0.44 | |
| Working capital | 45.87M | 41.56M | 56.27M | 55.36M | 52.32M | |
| Tangible asset value | 48.57M | 26.5M | 41.28M | 42.11M | 41.99M | |
| Net current asset value | 44.43M | 39.87M | 54.88M | 53.84M | 48.73M | |
| Invested capital | 0.02 | 0.05 | 0.02 | 0.02 | 0.05 | |
| Average receivables | 19.33M | 26.4M | 33.35M | 32.53M | 29.42M | |
| Average payables | 9.19M | 8.56M | 7.76M | 8.67M | 7.77M | |
| Average inventory | 18.57M | 18.37M | 18.88M | 25.32M | 26.28M | |
| Days sales outstanding | 122.25 | 153.23 | 125.89 | 127.18 | 129.18 | |
| Days payables outstanding | 98.03 | 69.96 | 53.45 | 70.86 | 46.03 | |
| Days of inventory on hand | 200.55 | 158.76 | 138.42 | 226.86 | 168.44 | |
| Receivables turnover | 2.99 | 2.38 | 2.9 | 2.87 | 2.83 | |
| Payables turnover | 3.72 | 5.22 | 6.83 | 5.15 | 7.93 | |
| Inventory turnover | 1.82 | 2.3 | 2.64 | 1.61 | 2.17 | |
| ROE | 0.09 | 0.05 | 0.09 | -0.01 | 0.01 | |
| Capex per share | -0.01 | -0.04 | -0.02 | -0.04 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.57 | 0.65 | 0.51 | 0.74 | 0.56 | |
| Net income per share | 0 | -0.01 | 0.02 | 0 | -0.02 | |
| Operating cash flow per share | 0.06 | -0.06 | 0.03 | 0.21 | 0.07 | |
| Free cash flow per share | 0.04 | -0.09 | -0.01 | 0.16 | 0.04 | |
| Cash per share | 0.34 | 0.21 | 0.19 | 0.32 | 0.3 | |
| Book value per share | 1.24 | 1.21 | 1.24 | 1.23 | 1.2 | |
| Tangible book value per share | 0.67 | 0.62 | 0.62 | 0.62 | 0.53 | |
| Share holders equity per share | 1.24 | 1.21 | 1.24 | 1.23 | 1.2 | |
| Interest debt per share | 0.02 | 0.03 | 0.03 | 0.07 | 0.06 | |
| Market cap | 219.4M | 109.7M | 80.59M | 65.35M | 76.86M | |
| Enterprise value | 197.93M | 97.3M | 69.48M | 48.17M | 60.43M | |
| P/E ratio | -391.78 | -50.23 | 15.21 | -51.54 | -14.7 | |
| Price to sales ratio | 5.7 | 2.51 | 2.31 | 1.3 | 2.02 | |
| POCF ratio | 58.07 | -26.52 | 42.19 | 4.63 | 16.19 | |
| PFCF ratio | 76.55 | -17.95 | -124.94 | 6.12 | 27.21 | |
| P/B Ratio | 2.62 | 1.34 | 0.96 | 0.78 | 0.94 | |
| PTB ratio | 2.62 | 1.34 | 0.96 | 0.78 | 0.94 | |
| EV to sales | 5.14 | 2.23 | 1.99 | 0.95 | 1.59 | |
| Enterprise value over EBITDA | 53.73 | 154.69 | 59.28 | 9.22 | 104.91 | |
| EV to operating cash flow | 52.39 | -23.53 | 36.38 | 3.42 | 12.73 | |
| EV to free cash flow | 69.06 | -15.92 | -107.72 | 4.51 | 21.39 | |
| Earnings yield | 0 | 0 | 0.02 | 0 | -0.02 | |
| Free cash flow yield | 0.01 | -0.06 | -0.01 | 0.16 | 0.04 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | |
| Debt to assets | 0.01 | 0.02 | 0.02 | 0.04 | 0.04 | |
| Net debt to EBITDA | -5.83 | -19.72 | -9.48 | -3.29 | -28.54 | |
| Current ratio | 3.82 | 4.12 | 3.9 | 3.36 | 3.16 | |
| Interest coverage | 50.66 | -8.9 | 2.82 | 8.26 | -3.69 | |
| Income quality | -26.99 | 7.58 | 1.44 | -44.48 | -3.63 | |
| Dividend Yield | 0 | 0.03 | 0.02 | 0 | 0.04 | |
| Payout ratio | 0 | -5.29 | 1.37 | 0 | -2.15 | |
| Sales general and administrative to revenue | 0.28 | 0.3 | 0.29 | 0.32 | 0.37 | |
| Research and developement to revenue | 0.09 | 0.12 | 0.08 | 0.06 | 0.06 | |
| Intangibles to total assets | 0.44 | 0.46 | 0.3 | 0.44 | 0.47 | |
| Capex to operating cash flow | -0.24 | 0.48 | -1.34 | -0.24 | -0.4 | |
| Capex to revenue | -0.02 | -0.05 | -0.07 | -0.07 | -0.05 | |
| Capex to depreciation | -0.91 | -1.99 | -2.83 | -2.37 | -1.62 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0 | 0.01 | |
| Graham number | 0.24 | 0.47 | 0.74 | 0.36 | 0.72 | |
| ROIC | 0 | 0.01 | 0 | 0.03 | -0.01 | |
| Return on tangible assets | 0 | -0.01 | 0.02 | 0 | -0.02 | |
| Graham Net | 0.56 | 0.47 | 0.43 | 0.44 | 0.39 | |
| Working capital | 59.62M | 55.36M | 54.23M | 52.32M | 46.59M | |
| Tangible asset value | 45.3M | 42.11M | 60.04M | 41.99M | 36M | |
| Net current asset value | 59.07M | 53.84M | 52.56M | 48.73M | 43.38M | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 73.35 | 58.96 | 70.31 | 53.86 | 65.96 | |
| Days payables outstanding | 77.14 | 43.74 | 60.78 | 46.9 | 60.06 | |
| Days of inventory on hand | 110.67 | 101.78 | 150.79 | 72.36 | 77.96 | |
| Receivables turnover | 1.23 | 1.53 | 1.28 | 1.67 | 1.36 | |
| Payables turnover | 1.17 | 2.06 | 1.48 | 1.92 | 1.5 | |
| Inventory turnover | 0.81 | 0.88 | 0.6 | 1.24 | 1.15 | |
| ROE | 0 | -0.01 | 0.02 | 0 | -0.02 | |
| Capex per share | -0.01 | -0.03 | -0.04 | -0.05 | -0.03 |
EAH.L Frequently Asked Questions
What is ECO Animal Health Group plc stock symbol ?
ECO Animal Health Group plc is a GB stock and trading under the symbol EAH.L
What is ECO Animal Health Group plc stock quote today ?
ECO Animal Health Group plc stock price is $94.24 today.
Is ECO Animal Health Group plc stock public?
Yes, ECO Animal Health Group plc is a publicly traded company.
Company Profile
- Volume Average 161.46K
- Market Capitalization 64.36M
- Employee 234
- CEO Mr. David Charles Hallas
- Headquarters New Malden,GB
- IPO Date 1995-09-26
-
Website
https://www.ecoanimalhealthgroupplc.com 
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is headquartered in New Malden, the United Kingdom.
